How Mis- And Disinformation Campaigns Online Kneecap Coronavirus Response
The pandemic has been marked by a significant amount of misinformation — some spread on purpose — that could prove deadly.
FDA
301 - 320 of 466 Results
-
-
As Problems Grow With Abbott’s Fast COVID Test, FDA Standards Are Under Fire
After the FDA issues a public warning about the test, one of its senior officials says point-of-care coronavirus tests can miss 20% of cases and still be considered useful. Public health experts are split.
-
Easy To Say ‘Get Tested.’ Harder To Do. Here’s How.
If you’ve been in a crowd — a protest or rally — experts have advice for figuring out whether you might have been exposed to the coronavirus, and where and when to get tested for it.
By Bernard J. Wolfson and Phil Galewitz -
KHN’s ‘What the Health?’: SCOTUS, Trump Collide Over Transgender Rights
The Trump administration rolled back protections for transgender patients just days before the Supreme Court cemented LGBTQ rights under the Civil Rights Act. So, what now? Meanwhile, coronavirus politics reaches beyond health care settings. Anna Edney of Bloomberg News, Tami Luhby of CNN and Shefali Luthra of KHN join KHN’s Julie Rovner to discuss this and more. Also, for extra credit, the panelists recommend their favorite health stories of the week they think you should read, too.
-
Hype Collides With Science As FDA Tries To Rein In ‘Wild West’ of COVID Blood Tests
Amid questions about the accuracy of the COVID-19 antibody tests flooding the market — and the usefulness of the results they provide — the FDA has belatedly stepped in to try to rein in the chaos.
-
Antibody Tests Were Hailed As Way To End Lockdowns. Instead, They Cause Confusion.
Some communities considered community antibody testing as a way out of lockdown. But they've pulled back as they realized antibody testing is the Wild West in an oversight vacuum.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
Abbott’s Fast COVID Test Poses Safety Issues, Lab Workers Say
HHS said this test would “save personal protective equipment.” But Abbott’s very design ― devised for mobile testing — means those working with specimens need even more protection, experts warn.
-
Amid Pandemic, FDA Seizes Cheaper Drugs From Canada
Many Americans order drugs from Canada and other countries because they are cheaper, but U.S. authorities appear to be cracking down on the practice.
-
Must-Reads Of The Week From Brianna Labuskes
Newsletter editor Brianna Labuskes wades through hundreds of health care policy stories each week, so you don't have to.
-
KHN’s ‘What The Health?’: How Will We Reopen The Economy?
The politics of COVID-19 are pretty polarized, but health experts across the ideological spectrum agree: The U.S. will need more robust testing before it’s safe to relax social-distancing requirements. Meanwhile, President Donald Trump, Congress and the nation’s governors continue to spar over who should be responsible for what. Kimberly Leonard of Business Insider, Tami Luhby of CNN and Anna Edney of Bloomberg News join KHN’s Julie Rovner to discuss this and more. Also, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.
-
A Desperate Scramble As COVID-19 Families Vie For Access To Plasma Therapy
As efforts ramp up to collect blood plasma from the first survivors of COVID-19, families of critically ill patients are jockeying to obtain the still-unproven antibody treatment.
-
‘You Pray That You Got The Drug.’ Ailing Couple Gambles On Trial For COVID-19 Cure
Josie and George Taylor of Everett, Washington, are two of the first people in the U.S. to recover from novel coronavirus infections after joining a clinical trial for the antiviral drug remdesivir.
-
Trump Touted Abbott’s Quick COVID-19 Test. HHS Document Shows Only 5,500 Are On Way For Entire U.S.
States urgently need millions of tests, and the game changer they’ve been waiting on falls well short of what is needed, according to government documents obtained by KHN.
-
Online Coronavirus Tests Are Just The Latest Iffy Products Marketed To Anxious Consumers
Americans are worried about the novel coronavirus, so they are turning to the internet for solutions to stem their fears. Buyer, beware. It could be dangerous.
-
What Takes So Long? A Behind-The-Scenes Look At The Steps Involved In COVID-19 Testing
A common complaint about the testing process is the long turnaround time for results.
-
As Coronavirus Testing Gears Up, Specialized Swabs Running Out
Nationwide, testing for coronavirus is ramping up. But the supply of specialty swabs needed to collect potential coronavirus specimens can’t keep up with demand, creating a bottleneck in testing capabilities. So two top manufacturers are working with U.S. and Italian governments to increase production.
By Lauren Weber and Christina Jewett -
How Intrepid Lab Sleuths Ramped Up Tests As Coronavirus Closed In
Drs. Keith Jerome and Alex Greninger fast-tracked a test for the deadly new coronavirus weeks before it began spreading in the U.S. Their work has been key to detecting community transmission and ramping up the nation’s testing capacity.
-
Call For FDA To Withdraw Preterm Birth Drug Divides Doctors and Insurers
A study ordered by the Food and Drug Administration failed to prove that Makena, the only drug approved to prevent premature birth, is effective. While a panel of experts has recommended withdrawing the drug’s approval, many doctors are wary.